EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells

Xuan-Yu Chen, Zhuo-Xun Wu, Jing-Quan Wang, Qiu-Xu Teng, Hailin Tang, Qianwen Liu, Zhe-Sheng Chen, Wenkuan Chen

Frontiers in Pharmacology · 02.05.2024 · 15

DOI: 10.3389/fphar.2024.1400699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.05.2024. Verfasst von Xuan-Yu Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biotechnology, St. John's University, Queens, NY, United States. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic effect of chemotherapy and targeted therapy are known to be limited by drug resistance. Substantial evidence has shown that ATP-binding cassette (ABC) transporters P-gp and BCRP are significant contributors to multidrug resistance (MDR) in cancer cells. In this study, we demonstrated that a clinical-staged ATR inhibitor ceralasertib is susceptible to P-gp and BCRP-mediated MDR. The drug resistant cancer cells were less sensitive to ceralasertib compared to the parental cells. Moreover, ceralasertib resistance can be reversed by inhibiting the drug efflux activity of P-gp and BCRP. Interestingly, ceralasertib was able to downregulate the level of P-gp but not BCRP, suggesting a potential regulation between ATR signaling and P-gp expression. Furthermore, computational docking analysis predicted high affinities between ceralasertib and the drug-binding sites of P-gp and BCRP. In summary, overexpression of P-gp and BCRP are sufficient to confer cancer cells resistance to ceralasertib, underscoring their role as biomarkers for therapeutic efficacy.

Schlagwörter

Stichwörter der Autor:innen

ATP-binding cassette transportersATR inhibitorAZD6738BCRPP-glycoproteinceralasertibmultidrug resistance

Autor:innen und Institutionen

  • Institute for Biotechnology, St. John's University, Queens, NY, United States.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Zitieren

APA

Chen, X. Y., Wu, Z. X., Wang, J. Q., Teng, Q. X., Tang, H., Liu, Q., Chen, Z. S., & Chen, W. (2024). Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1400699

Vancouver

Chen XY, Wu ZX, Wang JQ, Teng QX, Tang H, Liu Q, et al. Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1400699

BibTeX
@article{Chen2024,
  author = {Chen, Xuan-Yu and Wu, Zhuo-Xun and Wang, Jing-Quan and Teng, Qiu-Xu and Tang, Hailin and Liu, Qianwen and Chen, Zhe-Sheng and Chen, Wenkuan},
  title = {Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1400699}
}
Kostenlos starten →